Greater Cannabis Company (GCAN) Total Non-Current Liabilities (2016 - 2021)
Greater Cannabis Company (GCAN) recorded quarterly Total Non-Current Liabilities of $460651.0 in Q1 2021, up 4.11% quarter-over-quarter from $442467.0 in Q4 2020, and down 53.71% on a YoY basis from $995119.0 in Q1 2020.
Greater Cannabis Company (GCAN) Total Non-Current Liabilities (2016 - 2021) Analysis & Trends
Greater Cannabis Company's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $460651.0 for Q1 2021.
- In Q1 2021, Total Non-Current Liabilities fell 53.71% year-over-year to $460651.0; the TTM figure through Mar 2021 stood at $460651.0 (down 53.71% YoY), while the FY2020 annual figure was $442467.0, down 72.03% from the prior year.
- Total Non-Current Liabilities was $460651.0 for Q1 2021 at Greater Cannabis Company, up from $442467.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.6 million in Q4 2019 to a low of -$205403.0 in Q4 2017.
- Historically, Total Non-Current Liabilities has averaged $517437.2 across 5 years, with a median of $459956.0 in 2019.
- The sharpest annual moves came in 2017 and 2018: Total Non-Current Liabilities sank 2437.31% in 2017, then jumped 394.54% in 2018.
- A 5-year view of Total Non-Current Liabilities shows it stood at -$205403.0 in 2017, then jumped by 394.54% to $604999.0 in 2018, then jumped by 161.46% to $1.6 million in 2019, then plunged by 72.03% to $442467.0 in 2020, then gained by 4.11% to $460651.0 in 2021.
- The last three Total Non-Current Liabilities figures came in at $460651.0 (Q1 2021), $442467.0 (Q4 2020), and $599261.0 (Q3 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Greater Cannabis Company | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 460,651.00 |
| Dec 31, 2020 | 442,467.00 |
| Sep 30, 2020 | 599,261.00 |
| Jun 30, 2020 | 774,453.00 |
| Mar 31, 2020 | 995,119.00 |
| Dec 31, 2019 | 1.58 Mn |
| Sep 30, 2019 | 508,947.00 |
| Jun 30, 2019 | 459,956.00 |
| Mar 31, 2019 | 409,882.00 |
| Dec 31, 2018 | 604,999.00 |
| Sep 30, 2018 | 401,874.00 |
| Jun 30, 2018 | 274,624.00 |
| Mar 31, 2018 | 217,776.00 |
| Dec 31, 2017 | -205,403.00 |
| Sep 30, 2017 | 235,097.00 |
| Dec 31, 2016 | 8,788.00 |